Literature DB >> 16012868

[Treating depressive disorders with continuation electroconvulsive therapy].

A Sartorius1, F A Henn.   

Abstract

Nowadays, electroconvulsive therapy (ECT) is undergoing a renaissance in psychiatry: it is now considered a first-line therapy for treating psychotic depression or other disorders with severe depressive symptoms. Surprisingly, ECT is most commonly not used as continuation therapy after acute remission. With rare exceptions, antidepressive medication is chosen for this purpose. The use of continuation ECT (cECT) and subsequent maintenance ECT (mECT) is not or just marginally mentioned in practice guidelines. In this article, we suggest guidelines for cECT, taking therapy recommendations and recent studies into account. Particularly, indication, management, comedication and comorbidity, side effects, and costs are examined. Today, cECT is underindicated as a result of assumed problems, fears, and stigmas. We would therefore recommend broader use of this proven treatment tool for keeping major depression in remission.

Entities:  

Mesh:

Year:  2005        PMID: 16012868     DOI: 10.1007/s00115-005-1919-4

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  25 in total

Review 1.  A review of continuation and maintenance electroconvulsive therapy.

Authors:  K Rabheru; E Persad
Journal:  Can J Psychiatry       Date:  1997-06       Impact factor: 4.356

Review 2.  Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments.

Authors:  S H Kennedy; R W Lam; N L Cohen; A V Ravindran
Journal:  Can J Psychiatry       Date:  2001-06       Impact factor: 4.356

3.  Cost effectiveness of maintenance ECT.

Authors:  D C Steffens; A D Krystal; T E Sibert; S D Moore; R D Weiner
Journal:  Convuls Ther       Date:  1995-12

4.  Impact of maintenance ECT on concentration and memory.

Authors:  C J Datto; S Levy; D S Miller; I R Katz
Journal:  J ECT       Date:  2001-09       Impact factor: 3.635

5.  ECT in bipolar and unipolar depression: differences in speed of response.

Authors:  J J Daly; J Prudic; D P Devanand; M S Nobler; S H Lisanby; S Peyser; S P Roose; H A Sackeim
Journal:  Bipolar Disord       Date:  2001-04       Impact factor: 6.744

6.  Cognitive impairment in the euthymic phase of affective disorder.

Authors:  L V Kessing
Journal:  Psychol Med       Date:  1998-09       Impact factor: 7.723

7.  The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression.

Authors:  H A Sackeim; J Prudic; D P Devanand; P Decina; B Kerr; S Malitz
Journal:  J Clin Psychopharmacol       Date:  1990-04       Impact factor: 3.153

8.  Seizure expression during electroconvulsive therapy: relationships with clinical outcome and cognitive side effects.

Authors:  Tarique D Perera; Bruce Luber; Mitchell S Nobler; Joan Prudic; Christopher Anderson; Harold A Sackeim
Journal:  Neuropsychopharmacology       Date:  2004-04       Impact factor: 7.853

9.  Lithium-discontinuation-induced refractoriness: preliminary observations.

Authors:  R M Post; G S Leverich; L Altshuler; K Mikalauskas
Journal:  Am J Psychiatry       Date:  1992-12       Impact factor: 18.112

10.  Cost reduction with maintenance ECT in refractory bipolar disorder.

Authors:  C Bonds; M A Frye; M F Coudreaut; M Cunningham; M Spearing; M McGuire; B Guze
Journal:  J ECT       Date:  1998-03       Impact factor: 3.635

View more
  3 in total

1.  [Ketamine as anesthetic agent in electroconvulsion therapy].

Authors:  C Janke; J M Bumb; S S Aksay; M Thiel; L Kranaster; A Sartorius
Journal:  Anaesthesist       Date:  2015-05-06       Impact factor: 1.041

2.  [Health service aspects of electroconvulsive therapy: analysis of external referrals to a university medical center].

Authors:  Isabel Methfessel; Michael Belz; Fabienne Bühler; David Zilles-Wegner
Journal:  Nervenarzt       Date:  2022-08-11       Impact factor: 1.297

Review 3.  Electroconvulsive therapy and its different indications.

Authors:  Thomas C Baghai; Hans-Jürgen Möller
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.